Green MF, Harvey PD. Cognition in schizophrenia: past, present, and future. Schizophr Res Cogn. 2014;1:e1–e9.

Article  PubMed  Google Scholar 

Gisselgard J, Anda LG, Bronnick K, Langeveld J, Ten Velden Hegelstad W, Joa I, et al. Verbal working memory deficits predict levels of auditory hallucination in first-episode psychosis. Schizophr Res. 2014;153:38–41.

Article  PubMed  Google Scholar 

Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J psychiatry. 1996;153:321–30.

Article  PubMed  CAS  Google Scholar 

Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res. 2004;70:175–86.

Article  PubMed  Google Scholar 

Censits DM, Ragland JD, Gur RC, Gur RE. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res. 1997;24:289–98.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heilbronner U, Samara M, Leucht S, Falkai P, Schulze TG. The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects. Harv Rev Psychiatry. 2016;24:118–28.

Article  PubMed  PubMed Central  Google Scholar 

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen psychiatry. 2007;64:633–47.

Article  PubMed  CAS  Google Scholar 

Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2017;247:130–38.

Article  PubMed  PubMed Central  Google Scholar 

Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N. Anti-dementia drugs for psychopathology and cognitive impairment in schizophrenia: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2018;21:748–57.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sinkeviciute I, Begemann M, Prikken M, Oranje B, Johnsen E, Lei WU, et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophr. 2018;4:22.

Article  PubMed  PubMed Central  Google Scholar 

Lodge DJ. Circuit-based interventions for the treatment of behaviors relevant to Schizophrenia. Biol psychiatry. 2020;88:673–74.

Article  PubMed  PubMed Central  Google Scholar 

Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA. Arch Neurol psychiatry. 1959;81:363–9.

Article  CAS  Google Scholar 

Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J psychiatry. 1991;148:1301–8.

Article  PubMed  CAS  Google Scholar 

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen psychiatry. 1994;51:199–214.

Article  PubMed  CAS  Google Scholar 

Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol 1996;14:301–7.

Article  CAS  Google Scholar 

Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol 1997;17:92–9.

Article  CAS  Google Scholar 

Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport. 2001;12:11–5.

Article  PubMed  CAS  Google Scholar 

Scheggia D, Bebensee A, Weinberger DR, Papaleo F. The ultimate intra-/extra-dimensional attentional set-shifting task for mice. Biol Psychiatry. 2014;75:660–70.

Article  PubMed  Google Scholar 

Arime Y, Akiyama K. Abnormal neural activation patterns underlying working memory impairment in chronic phencyclidine-treated mice. PLoS One. 2017;12:e0189287.

Article  PubMed  PubMed Central  Google Scholar 

Perez MA, Morales C, Santander O, Garcia F, Gomez I, Penaloza-Sancho V, et al. Ketamine-treatment during late adolescence impairs inhibitory synaptic transmission in the prefrontal cortex and working memory in adult rats. Front Cell Neurosci. 2019;13:372.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162–94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134:219–25.

Article  PubMed  Google Scholar 

Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17:97–103.

Article  PubMed  Google Scholar 

Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497–502.

Article  PubMed  CAS  Google Scholar 

Arime Y, Fukumura R, Miura I, Mekada K, Yoshiki A, Wakana S, et al. Effects of background mutations and single nucleotide polymorphisms (SNPs) on the Disc1 L100P behavioral phenotype associated with schizophrenia in mice. Behav Brain Funct. 2014;10:45.

Article  PubMed  PubMed Central  Google Scholar 

Dumitriu D, Rodriguez A, Morrison JH. High-throughput, detailed, cell-specific neuroanatomy of dendritic spines using microinjection and confocal microscopy. Nat Protoc. 2011;6:1391–411.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Elsworth JD, Morrow BA, Hajszan T, Leranth C, Roth RH. Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine. Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol. 2011;36:2054–61.

Article  CAS  Google Scholar 

Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron. 2001;31:247–60.

Article  PubMed  CAS  Google Scholar 

Kubota Y, Hatada S, Kondo S, Karube F, Kawaguchi Y. Neocortical inhibitory terminals innervate dendritic spines targeted by thalamocortical afferents. J Neurosci. 2007;27:1139–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chamberlin LA, Yang SS, McEachern EP, Lucas JTM, McLeod Ii OW, Rolland CA, et al. Pharmacogenetic activation of parvalbumin interneurons in the prefrontal cortex rescues cognitive deficits induced by adolescent MK801 administration. Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol. 2023;48:1267–76.

Gogolla N, Takesian AE, Feng G, Fagiolini M, Hensch TK. Sensory integration in mouse insular cortex reflects GABA circuit maturation. Neuron. 2014;83:894–905.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 2017;357:503–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nagai Y, Miyakawa N, Takuwa H, Hori Y, Oyama K, Ji B, et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nat Neurosci. 2020;23:1157–67.

Article  PubMed  CAS  Google Scholar 

Kamigaki T, Dan Y. Delay activity of specific prefrontal interneuron subtypes modulates memory-guided behavior. Nat Neurosci. 2017;20:854–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferguson BR, Gao WJ. Thalamic control of cognition and social behavior via regulation of gamma-aminobutyric acidergic signaling and excitation/inhibition balance in the medial prefrontal cortex. Biol Psychiatry. 2018;83:657–69.

Article  PubMed  CAS  Google Scholar 

Kaar SJ, Angelescu I, Marques TR, Howes OD. Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. J Neural Transm (Vienna). 2019;126:1637–51.

Article  PubMed  CAS  Google Scholar 

Dienel SJ, Schoonover KE, Lewis DA. Cognitive dysfunction and prefrontal cortical circuit alterations in schizophrenia: developmental trajectories. Biol Psychiatry. 2022;92:450–59.